Neurocrine Closer To Ingrezza Label Expansion With Huntington’s Chorea Phase III Win

 
• By Joseph Haas

The neuroscience-focused firm plans a 2022 supplemental NDA for Ingrezza following success in the pivotal KINECT-HD study. The biotech needed an R&D success after recent stumbles.

Brain research
Neurocrine thinks Ingrezza can better the competition in Huntington's chorea

More from Clinical Trials

More from R&D